260 related articles for article (PubMed ID: 31002722)
1. Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
Shirasawa M; Fukui T; Kusuhara S; Harada S; Nishinarita N; Hiyoshi Y; Ishihara M; Kasajima M; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
PLoS One; 2019; 14(4):e0214599. PubMed ID: 31002722
[TBL] [Abstract][Full Text] [Related]
2. Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.
Xu LM; Cheng C; Kang M; Luo J; Gong LL; Pang QS; Wang J; Yuan ZY; Zhao LJ; Wang P
Sci Rep; 2017 Aug; 7(1):9255. PubMed ID: 28835666
[TBL] [Abstract][Full Text] [Related]
3. Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M; Kanda S; Koizumi T
Chemotherapy; 2019; 64(3):129-137. PubMed ID: 31622969
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
[TBL] [Abstract][Full Text] [Related]
5. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
10. Can consolidative thoracic radiotherapy improve outcomes in extensive-disease small cell lung cancer after chemotherapy with complete/near-complete responders?
Kirakli EK; Yilmaz H; Akcay C; Komurcuoglu B; Yilmaz U
J Cancer Res Ther; 2020; 16(4):752-756. PubMed ID: 32930114
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity.
Ou SH; Ziogas A; Zell JA
J Thorac Oncol; 2009 Jan; 4(1):37-43. PubMed ID: 19096304
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.
Foster NR; Mandrekar SJ; Schild SE; Nelson GD; Rowland KM; Deming RL; Kozelsky TF; Marks RS; Jett JR; Adjei AA
Cancer; 2009 Jun; 115(12):2721-31. PubMed ID: 19402175
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
14. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
Abdel-Rahman O
Clin Respir J; 2018 Oct; 12(10):2519-2524. PubMed ID: 30073795
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
16. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of survival following anti-cancer treatment for small cell lung cancer.
Jones GS; Elimian K; Baldwin DR; Hubbard RB; McKeever TM
Lung Cancer; 2020 Mar; 141():44-55. PubMed ID: 31955000
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
